OBJECTIVE: Parasympathetic dysfunction is an independent risk factor in individuals with coronary artery disease, and cholinergic stimulation is a potential therapeutical option. We determined the effects of pyridostigmine bromide, a reversible anticholinesterase agent, on electrocardiographic variables of healthy individuals. METHODS: We carried out a cross-sectional, double blind, randomized, placebo-controlled study. We obtained electrocardiographic tracings in 12 simultaneous leads of 10 healthy young individuals at rest before and after oral administration of 45 mg of pyridostigmine or placebo. RESULTS: Pyridostigmine increased RR intervals (before: 886±27 ms vs after: 1054±37 ms) and decreased QTc dispersion (before: 72±9ms vs after: ...
Objective. Donepezil, a widely used cholinesterase inhibitor for treating Alzheimer’s disease, has b...
QT prolongation and the risk of ventricular arrhythmias in humans remain a major concern during d...
371338339Congress of the European-Society-of-Cardiology (ESC)AUG 27-31, 2016Rome, ITAL
OBJECTIVE: Parasympathetic dysfunction is an independent risk factor in individuals with coronary ar...
Parasympathetic dysfunction is an independent risk factor in patients with coronary artery disease; ...
Abstract Pyridostigmine bromide (PB) is a reversible cholinesterase inhibitor. The aim of this study...
The cardiovascular electrophysiologic basis for the action of pyridostigmine, an acetylcholinesteras...
OBJECTIVE: Growing evidence suggests that sudden death after an acute myocardial infarction (AMI) co...
This double-blind, randomized, placebo crossover study was used to evaluate the effects of a Choline...
OBJETIVE: The evaluation, by exercise stress testing, of the cardiorespiratory effects of pyridostig...
The purpose of the present work was to verify the effect of pyridostigmine bromide, a reversible cho...
Pyridostigmine (PIR), a reversible anticholinestesic, has its cardioprotective effects demonstrated ...
AbstractSympathetic hyperactivity and its outcome in heart failure have been thoroughly investigated...
<div><p>The effect of pyridostigmine (PYR) - an acetylcholinesterase inhibitor - on hemodynamics and...
of the cardiorespiratory effects of pyridostigmine (PYR), a reversible acetylcholinesterase inhibit...
Objective. Donepezil, a widely used cholinesterase inhibitor for treating Alzheimer’s disease, has b...
QT prolongation and the risk of ventricular arrhythmias in humans remain a major concern during d...
371338339Congress of the European-Society-of-Cardiology (ESC)AUG 27-31, 2016Rome, ITAL
OBJECTIVE: Parasympathetic dysfunction is an independent risk factor in individuals with coronary ar...
Parasympathetic dysfunction is an independent risk factor in patients with coronary artery disease; ...
Abstract Pyridostigmine bromide (PB) is a reversible cholinesterase inhibitor. The aim of this study...
The cardiovascular electrophysiologic basis for the action of pyridostigmine, an acetylcholinesteras...
OBJECTIVE: Growing evidence suggests that sudden death after an acute myocardial infarction (AMI) co...
This double-blind, randomized, placebo crossover study was used to evaluate the effects of a Choline...
OBJETIVE: The evaluation, by exercise stress testing, of the cardiorespiratory effects of pyridostig...
The purpose of the present work was to verify the effect of pyridostigmine bromide, a reversible cho...
Pyridostigmine (PIR), a reversible anticholinestesic, has its cardioprotective effects demonstrated ...
AbstractSympathetic hyperactivity and its outcome in heart failure have been thoroughly investigated...
<div><p>The effect of pyridostigmine (PYR) - an acetylcholinesterase inhibitor - on hemodynamics and...
of the cardiorespiratory effects of pyridostigmine (PYR), a reversible acetylcholinesterase inhibit...
Objective. Donepezil, a widely used cholinesterase inhibitor for treating Alzheimer’s disease, has b...
QT prolongation and the risk of ventricular arrhythmias in humans remain a major concern during d...
371338339Congress of the European-Society-of-Cardiology (ESC)AUG 27-31, 2016Rome, ITAL